Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The phase 3 trial demonstrated noninferiority in immunogenicity against standard vaccines, but the primary evidence is based on immunobridging rather than direct clinical efficacy outcomes such as prevention of symptomatic COVID-19 or influenza. The EMA has noted the need for post-marketing effectiveness confirmation for the influenza component, indicating uncertainty about the extent of protection.
Cost effectiveness
There is a lack of public economic evidence for mRNA-1083, including no estimates for acquisition cost, administration cost, or ICER. The absence of a fully described economic model means that cost-effectiveness cannot be assessed, leading to a classification of non-cost-effective.
Quality of life
The study reported a transient decline in EQ-5D-5L utility scores post-vaccination, which was below the clinically meaningful threshold. While there were some short-term increases in work impairment, no caregiver burden data were provided, indicating a lack of comprehensive HRQoL assessment.
Supporting Domains
Safety and Adverse Effects
The safety profile indicates that reactogenicity was higher with mRNA-1083 compared to separate vaccines, but the adverse events were consistent with typical mRNA vaccine responses. No serious safety concerns were detected, although the EMA required monitoring for potential rare adverse events.
Comparator Selection
The phase 3 trial used appropriate age-appropriate comparators for both influenza and COVID-19 vaccines, aligning with current recommendations. The choice of comparators was deemed adequate by the EMA, supporting the relevance of the trial design.
Patient Population and Subgroups
The trial population was reasonably broad, but it was limited to U.S. sites and excluded clinically unstable conditions and severely frail individuals. This raises concerns about the generalizability of the findings to all older adults.
Care Pathway Integration
The product integrates seamlessly into existing vaccination pathways, requiring no new infrastructure or significant changes to current clinical practices. The administration process is straightforward, involving a single injection instead of two.
Resource Use and Cost Implications
While the potential for operational simplification exists by replacing two injections with one, there is no quantified evidence of resource savings or cost implications available in the public domain.
Evidence Quality and Robustness
The evidence is based on a large, randomized phase 3 trial with strong regulatory oversight. However, the reliance on immunobridging rather than direct clinical outcomes introduces some methodological concerns.
Uncertainty, Sensitivity, and Broader Impacts
There is significant uncertainty regarding the long-term efficacy and real-world effectiveness of the vaccine, particularly for the influenza component. The variability in vaccination policies across different markets adds to this uncertainty.
